Valeria Santini
0000-0002-5439-2172
University of Firenze
230 papers found
Refreshing results…
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Corrections to “Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines”
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study
Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study
Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
Of blood and bone: the sotatercept adventure
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations from the European Hematology Association and the European LeukemiaNet
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency
Missing publications? Search for publications with a matching author name.